Thyroid nodules are common, but it does not necessarily mean they require similar considerations. An odd symptom, a peculiar image finding, and doubtful biochemical results all may indicate the need for further investigations. The ThyroTrack is a MedGenome genetic test that uses next-gen sequencing to look for mutations in thyroid nodules to aid clinicians in thyroid tumor testing and deciding whether to go for surgery, treatment, or follow-up. This blog mentions some important clinical, symptomatology, and cytology symptoms that should alert one to the possibility of considering the ThyroTrack testing method.
What is ThyroTrack?
ThyroTrack is a test that employs next-generation sequencing to detect genetic changes in thyroid nodules. It searches for small mutations-and this includes SNVs and InDels-in 46 genes and gene fusions in 23 genes. The genes are selected per guideline recommendations (ATA 2015 and NCCN 2022).
When You Need To Pay Attention: Clinical And Cytology Triggers
Most thyroid nodules do not require extensive testing. Below are given the indications, symptoms, or cytology findings that could be considered for the utility of ThyroTrack:
1. Indeterminate cytology (Bethesda III & IV)
When an FNA biopsy yields an indeterminate diagnosis (Bethesda category III or IV), the pathologist determines that the cells cannot be distinctly classified as benign or malignant on their cellular characteristics. Because of this grey zone, ThyroTrack molecular genetic markers can be used to assess the risk that may favour malignancy.
2. Malignant cytology (Bethesda V & VI) when the treatment plan is unclear
When cytology indicates malignancy, molecular testing can be useful if it remains unclear whether aggressive surgery or additional therapy is necessary. ThyroTrack therefore helps direct the extent of surgical or other therapies.
3. Benign cytology but high clinical suspicion
Even with benign cytology (Bethesda II), ThyroTrack may be considered if clinical or ultrasound findings raise unusual suspicion of malignancy. This is because cytology cannot provide an absolute diagnosis, and imaging or clinical context may suggest risk.
4. Cytologically insufficient sample (Bethesda I) plus suspicious imaging
Sometimes, an FNA sample has insufficient cells (Bethesda I). If imaging or ultrasound raises suspicion, molecular testing like ThyroTrack can help assess risk and potentially avoid repeating the procedure.
5. Confirmed cancer where the molecular profile will guide therapy
In cases where thyroid cancer becomes established (by cytology or histology), ThyroTrack can be used to determine the genetic profile, guiding management decisions such as radioactive iodine therapy, targeted treatment, or close follow-up.
Physical Symptoms & Imaging Signs To Watch For
Apart from the cytology findings, physical or imaging signs should be taken into account and brought to an additional thorough screening and possibly genetic testing:
- A lump or nodule in the neck, especially a new or growing one.
- Voice changes, such as hoarseness or difficulty swallowing or breathing, occur as a result of a nodule pressing against nearby structures.
- The thyroid nodule grows rapidly.
- Suspect features on ultrasound: irregular borders, microcalcifications, marked intranodular blood flow, heterogeneous internal structure, or hypoechogenicity.
- For these signs, an inconclusive cytology only increases the probability that molecular/genetic testing will be worthwhile.
What To Expect With Thyrotrack?
The following are some pragmatic considerations if the physician is recommending the test:
- The sample could be FNA fluid or tumour tissue post-surgery.
- Tumour purity must be sufficient. Various technical considerations (minimum tumour content, minimum variant allele fraction) need to be fulfilled for the method to give accurate detection.
The turnaround is about 14 working days, from the moment the sample reaches the laboratory.
Conclusion
If one or more of the red flags mentioned earlier are present, suspicious imaging findings, indeterminate cytology, evidence of growth, or symptoms such as difficulty in swallowing or change of voice, then it is wise to talk about ThyroTrack with your doctor. Genetic testing does not always alter a clinical outcome, but it often reduces uncertainty and helps facilitate superior decision-making.
